Deciphering the role of microglia in Zika virus-induced neuroinflammation and pathogenesis during fetal brain development

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 558889

Grant search

Key facts

  • Disease

    Congenital infection caused by Zika virus
  • Start & end year

    2025
  • Known Financial Commitments (USD)

    $1,047.57
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Olus Uyar
  • Research Location

    Canada
  • Lead Research Institution

    INRS - (Québec, QC)
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics
  • Research Subcategory

    Pathogen morphology, shedding & natural history
  • Special Interest Tags

    N/A
  • Study Type

    Non-Clinical
  • Clinical Trial Details

    N/A
  • Broad Policy Alignment

    Pending
  • Age Group

    Not Applicable
  • Vulnerable Population

    Not applicable
  • Occupations of Interest

    Not applicable

Abstract

Infections with Zika virus (ZIKV) constitute a major global public health concern worldwide. Indeed, the recent ZIKV outbreak in the Americas revealed that infection of pregnant women can lead to congenital transmission, infection within the fetal developing brain, and eventually microcephaly in the infant. Most importantly, no antiviral therapies or vaccine against ZIKV are currently available, as we poorly understand the relative contribution of resident and infiltrating immune cells and neural progenitor cells to the disease. Relying on our wide expertise in virology and neurodevelopment, this proposal aims to better understand ZIKV pathogenesis in the developing brain in vivo by taking advantage of our innovative in utero mouse fetal brain infection model recently developed by our team. We will characterize the contribution of brain-specific macrophages (named microglia) to ZIKV-induced neuroinflammation and microcephaly. This project will contribute to a better understanding of the etiology of ZIKV neuropathogenesis and might identify promising antiviral targets for drug development.